

Setting our sights on infectious diseases

A WCAIR CONFERENCE ON DRUG DISCOVERY & DEVELOPMENT

12-15 May 2019, University of Dundee

Please note programme is preliminary - timings are to be confirmed.

Speakers correct at time of writing

Sessions will take place in Lecture Theatre 3 on the first floor of the Dalhousie Building, University of Dundee. Breaks and lunch will be co-located with the posters in the Dalhousie Foyer and level 1 gallery.

SUNDAY 12TH MAY

SESSION 1: THE CURRENT SITUATION

The aim of this session is to highlight the current situation in infectious diseases, future risks, where the current needs are. What is the current situation with regards to drug discovery for infectious diseases. An overview of how can we do drug discovery and development better. What is the role of government and industry?

Professor Sir Nick White, Mahidol University	17.00-17.40	The global situation
Professor Shyam Sundar, Banaras Hindu University	17.40-18.20	Current and future clinical treatment of leishmaniasis
Professor Paul Herrling	18.20-19.00	How can we do drug discovery more effectively? Who are the key players and how can we bring them together?

19.15: Welcome reception in the School of Life Sciences The Street and LifeSpace.

MONDAY 13TH MAY

SESSION 2: CLINICAL DEVELOPMENT AND CONNECTIVITY TO THE PRECLINICAL SITUATION

The aim of this session is look at new ways of doing clinical trials. How can we accelerate clinical development of new compounds? How can we link the clinical situation to the preclinical situation?

Dr Clif Barry, NIH National Institute of Allergy and Infectious Diseases	09.00-09.40	Clinical trials for TB. Use of imaging in clinical trials. How does what you see preclinically relate to what you see clinically
Professor James McCarthy, Royal Brisbane and Woman's Hospital	09.40-10.20	Use of human challenge models in clinical development of compounds
Dr Isabela Ribeiro, Drugs for Neglected Diseases Initiative	10.20-11.00	Clinical trials for Chagas Disease. Understanding clinical PK/PD relationships. How can we do trials for Chagas disease better.
Coffee	11.00-11.30	Posters
Short talks	11.30-12.10	Talks selected from submitted abstracts
Panel Discussion	12.10-12.30	
Lunch and Posters	12.30-14.00	Dalhousie Foyer

SESSION 3: COMBINATION THERAPY: CLINICAL AND PRECLINICAL SELECTION

The aim of this session is to explore how effective combinations are in the treatment of infectious diseases. What makes a good combination and how are these selected? How good are preclinical and animal models for selecting combinations?

Dr Didier Leroy, Medicines for Malaria Venture	14.00-14.40	Preclinical and clinical selection of antimalarial combinations
Dr Bree Aldridge, Tufts University	14.40-15.20	Selection of combinations for TB treatment.
Dr John Pottage, ViiV Healthcare	15.20-16.00	How do you select a combination treatment for HIV? What factors make a good combination?
Coffee/ Tea	16.00-16.30	Posters
Short talks	16.30-17.00	Talks selected from submitted abstracts
Panel Discussion	17.00-17.30	

19.00: Social event with dinner at Discovery Point.

TUESDAY 14TH MAY

SESSION 4: PK/PD STUDIES AND ANIMAL MODELS

This session will focus on modern approaches to understanding PK/PD relationships and how this can help in developing compounds.

Professor Wes van Voorhis, Center for Emerging and Re-emerging Infectious Diseases , University of Washington	09.00-09.40	Challenges in the discovery of new agents for cryptosporidiosis and understanding their PK/PD relationships
Dr Nathalie Gobeau, Medicines for Malaria Venture	09.40-10.20	PK/PD modelling in malaria
Dr Thomas Spangenberg, Merck	10.20-11.00	PK/PD Studies with Schistosomiasis
Coffee	11.00-11.30	Posters
Short talks	11.30-12.00	Talks selected from submitted abstracts
Panel Discussion	12.00-12.30	
Lunch and Posters	12.30-14.00	Dalhousie Foyer

SESSION 5: DRUG DISCOVERY PATHWAYS

How do we develop the drug discovery pathway. Choosing the critical pathway. How do we make sure our assays are relevant to the clinical situation?

Dr Manu de Rycker, Wellcome Centre for Anti-Infectives Research	14.00-14.40	Development of screening cascades for kinetoplastid parasites.
Associate Professor Jennifer Keiser, Swiss Tropical and Public Health Institute	14.40-15.20	Cellular and animal models for helminth infections. Approaches being used to discover new start points.
Professor Valerie Mizrahi, Institute of Infectious Disease and Molecular Medicine, UCT	15.20-16.00	The screening cascade for TB. How biology and chemistry are integrated to select compounds going forwards.
Coffee/ Tea	16.00-16.30	Posters
Short talks	16.30-17.00	Talks selected from submitted abstracts
Panel Discussion	17.00-17.30	

19.00: Social event with dinner at V&A Dundee (To be confirmed).

WEDNESDAY 15TH MAY

SESSION 6: NEW START POINTS AND TARGETS

The aims of this session are how to identify new drug targets are found and how can we be smarter and faster in how we do early phase drug discovery.

Dr Susan Wyllie, Wellcome Centre for Anti-Infectives Research	09.00-09.40	Target deconvolution of phenotypic hits as a way of identifying drug targets
tbc	09.40-10.20	
Dr Paul Leeson, Consultant	10.20-11.00	How do you choose the right compounds to make? What properties do you need in a new drug? What are the learnings for infectious disease drug discovery.
Coffee	11.00-11.30	Posters
Short talks	11.30-12.00	Talks selected from submitted abstracts
Panel Discussion	12.00-12.30	
Lunch	12.30-13.30	Posters
Dr Lynne Silver, Consultant	13.30-14.10	What makes a good antibacterial drug target and what makes a good antibacterial molecule?
Dr John Overington, Medicines Discovery Catapult	14.10-14.50	Use of AI in drug discovery.
Wrap Up	14.50-15.00	
	15.00	End of conference